July 21, 2011 (Paris) -- An experimental drug that targets one of the underlying processes that may cause Alzheimer's disease may be safer over the long run than previously thought, researchers say.
Early studies of the drug, bapineuzumab, raised a red flag when some patients developed troublesome brain swelling that can lead to headache, loss of coordination, weakness, disorientation, memory loss, and hallucinations.
New longer-term safety data on bapineuzumab suggest that although the brain swelling may be more common than first reported, the risk appears to decline the longer a person is taking the drug.
Also, the brain swelling is often mild, causing no symptoms, according to the research presented here at the Alzheimer's Association International Conference.
Bapineuzumab is a monoclonal antibody designed to bind to and clear beta-amyloid plaque from the brain. Current belief holds that the plaque starts to build up in the brain seven to 10 years prior to the decline in cognitive skills that is often the first symptom of Alzheimer's.
The hope is that disease-modifying drugs like bapineuzumab will work early in the disease process, delaying mental decline and slowing the progressive degeneration of brain tissue. A number of the drugs, including bapineuzumab, are in late-stage phase III trials, but so far none has been approved by the FDA.
In animal research and early human studies, bapineuzumab appeared to work just as it was supposed to. But as the side effect of brain swelling surfaced -- formerly called vascular edema and now known as amyloid-related imaging abnormalities, or ARIA -- so did safety concerns.
The new findings "give us encouragement going forward," says Stephen Salloway, MD, professor of neurology at Brown Medical School.